Phytochemicals targeting ubiquitin-dependent mitophagy and apoptosis in sarcopenia: a review
This abstract reviews how ubiquitin-linked mitochondrial cleanup, protein breakdown and cell-death programmes interact in sarcopenia, and how phytochemicals might act on these targets; low oral bioavailability and missing phase III trials limit translation. [1]
Automatic summary · not editorially reviewed
The key findings
Sarcopenia is described as affecting approximately 10–16% of the global older adult population. [1]
The review analyses how phytochemicals achieve autophagy-promoting, anti-apoptotic and anti-degradative protection of skeletal muscle. [1]
Oral bioavailability of phytochemicals is often below 1%, and phase III clinical trials are absent. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Older adults with sarcopenia, as described in the review; no specific participants were studied in this abstract.
- Summary based on
- Study abstract
- Original publication
- October 19, 2026
Sarcopenia review on ubiquitin, mitophagy and phytochemicals
Sarcopenia is described as a progressive degenerative disease of skeletal muscle linked to aging, disuse and chronic diseases, affecting about 10–16% of older adults worldwide. The abstract says its core pathological basis involves disrupted protein balance in skeletal muscle cells and mitochondrial dysfunction. The review asks how ubiquitin-dependent processes — mitochondrial cleanup, protein hydrolysis and escape from apoptosis — interact, and whether phytochemicals can act on them.
Supporting source [1]
Review of mechanisms, not a new trial in people
This is a review article, not a new study. According to the abstract, it analyses the dual-faceted regulatory mechanisms of ubiquitination in skeletal muscle mitochondrial quality control, protein hydrolysis and apoptosis escape. It also analyses how phytochemicals such as polyphenols, flavonoids, alkaloids and coumarins achieve autophagy-promoting, anti-apoptotic and anti-degradative skeletal muscle protection. The abstract further discusses nano-delivery systems and strategies based on the gut-muscle axis.
Supporting source [1]
Proposed multi-target effects and bioavailability limits
The abstract states that traditional single-target interventions often show limited therapeutic efficacy because the cell-fate network is complex and interconnected. Phytochemicals are credited with multi-target, multi-pathway synergistic regulation. However, the abstract notes that oral bioavailability is often below 1%, that metabolism depends on the microbiota, and that phase III clinical trials are absent — barriers to translational use. These are proposed mechanisms and review conclusions, not demonstrated human lifespan benefits.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a review, so no new participants, follow-up or outcomes are reported here. Proposed mechanisms and phytochemical effects are not established human benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zeng Y, Wang P. · europepmc.org · October 19, 2026